Profile data is unavailable for this security.
About the company
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
- Revenue in EUR (TTM)2.14bn
- Net income in EUR388.86m
- Incorporated--
- Employees4.46k
- LocationRecordati Industria Chimica e Farmaceutica SpAVia Matteo Civitali, 1MILANO 20148ItalyITA
- Phone+39 2487871
- Fax+39 240073747
- Websitehttps://recordati.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | 2.69bn | 177.59m | 5.18bn | 8.97k | 29.22 | 2.51 | 14.47 | 1.93 | 0.6742 | 0.6742 | 10.19 | 7.84 | 0.6284 | 1.76 | 3.67 | 252,815.30 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| Orion Oyj | 1.22bn | 216.80m | 5.31bn | 3.70k | 24.29 | 7.46 | 20.10 | 4.35 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| DiaSorin SpA | 1.15bn | 159.85m | 5.48bn | 3.23k | 34.18 | 3.40 | 18.56 | 4.77 | 2.87 | 2.87 | 21.49 | 28.83 | 0.3469 | 1.31 | 5.49 | 355,153.10 | 4.79 | 10.30 | 5.32 | 11.50 | 64.55 | 66.70 | 13.80 | 21.25 | 2.08 | 11.35 | 0.4368 | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
| Zealand Pharma A/S | 46.14m | -99.03m | 5.56bn | 270.00 | -- | 14.54 | -- | 120.57 | -12.52 | -12.52 | 5.78 | 45.56 | 0.1397 | 4.18 | 2.86 | 1,360,664.00 | -29.99 | -42.74 | -32.82 | -50.24 | 90.07 | 96.13 | -214.60 | -464.66 | 12.28 | -- | 0.1206 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Grifols SA | 6.66bn | 189.00m | 5.61bn | 23.74k | 32.67 | 1.05 | 7.89 | 0.8435 | 0.2813 | 0.2813 | 9.89 | 8.75 | 0.3074 | 1.18 | 7.07 | 280,331.60 | 1.31 | 2.39 | 1.68 | 3.04 | 38.63 | 40.26 | 4.27 | 7.54 | 1.02 | 1.78 | 0.5839 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
| BACHEM HOLDING AG | 605.91m | 117.40m | 6.24bn | 2.01k | 52.86 | 4.50 | 37.84 | 10.30 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Croda International Plc | 2.01bn | 202.70m | 6.83bn | 5.85k | 33.74 | 2.45 | 19.32 | 3.40 | 1.22 | 1.22 | 12.12 | 16.85 | 0.4713 | 2.40 | 4.39 | 289,559.10 | 4.79 | 10.80 | 5.42 | 12.51 | 43.08 | 46.41 | 10.16 | 18.64 | 1.77 | 17.07 | 0.2307 | 43.44 | -18.90 | 4.09 | -73.66 | -6.42 | 12.78 | 4.11 |
| Swedish Orphan Biovitrum AB (publ) | 2.06bn | 190.42m | 8.51bn | 1.75k | 43.62 | 2.56 | 17.22 | 4.13 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Qiagen NV | 1.84bn | 318.97m | 8.78bn | 5.97k | 27.93 | 2.48 | 17.18 | 4.78 | 1.43 | 1.43 | 8.21 | 16.08 | 0.3169 | 1.93 | 5.38 | 307,816.40 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Eurofins Scientific SE | 6.51bn | 516.50m | 10.06bn | 61.80k | 19.97 | 1.97 | 8.88 | 1.54 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
| Recordati Industria Chmc Frmctc SpA | 2.14bn | 388.86m | 10.06bn | 4.46k | 26.82 | 5.46 | 18.51 | 4.70 | 1.79 | 1.79 | 9.92 | 8.81 | 0.5177 | 1.67 | 4.53 | 480,087.10 | 9.41 | 11.67 | 12.13 | 15.02 | 67.82 | 70.43 | 18.18 | 21.45 | 0.9518 | 7.55 | 0.4883 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Ipsen SA | 3.31bn | 617.10m | 10.10bn | 5.33k | 16.30 | 2.61 | 10.55 | 3.05 | 7.39 | 7.72 | 39.66 | 46.25 | 0.554 | 1.99 | 5.23 | 620,920.20 | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.089 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| BioMerieux SA | 3.67bn | 357.60m | 10.75bn | 14.65k | 30.17 | 2.86 | 17.44 | 2.92 | 3.01 | 3.01 | 30.93 | 31.76 | 0.7036 | 1.97 | 5.00 | 250,815.60 | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sandoz Group AG | -104.95bn | -104.95bn | 14.37bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Recordati Industria Chimica e Farmaceutica SpA's reporting currency: Euro EUR
14.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Apr 2024 | 7.35m | 3.52% |
| Invesco Asset Management Ltd.as of 18 Mar 2024 | 4.76m | 2.28% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 3.63m | 1.73% |
| Fundsmith LLPas of 31 Dec 2022 | 3.26m | 1.56% |
| Mawer Investment Management Ltd.as of 31 Dec 2023 | 2.62m | 1.25% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 2.49m | 1.19% |
| Financi�re de l'�chiquier SAas of 28 Dec 2023 | 1.97m | 0.94% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.81m | 0.87% |
| Geode Capital Management LLCas of 13 Jun 2024 | 1.28m | 0.61% |
| Invesco Advisers, Inc.as of 18 Mar 2024 | 1.25m | 0.60% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
